N-(alpha-L-aspartyl)-2-naphthylamine : An L-aspartic acid derivative that is the amide obtained by formal condensation of the alpha-carboxy group of L-aspartic acid with the amino group of 2-naphthylamine.
ID Source | ID |
---|---|
PubMed CID | 16218971 |
CHEBI ID | 90425 |
MeSH ID | M0129605 |
Synonym |
---|
aspartic acid beta-naphthylamide |
635-91-6 |
l-aspartic acid alpha-(beta-naphthylamide) |
l-aspartic acid alpha-(2-naphthylamide) |
l-aspartic acid 2-naphthylamide |
l-aspartic acid beta-naphthylamide |
n-(alpha-l-aspartyl)-2-naphthylamine |
CHEBI:90425 |
l-aspartic acid 1-(2-naphthylamide) |
n-naphthalen-2-yl-l-alpha-asparagine |
AKOS027384354 |
(3s)-3-amino-4-(naphthalen-2-ylamino)-4-oxobutanoic acid |
mfcd00037739 |
h-asp-na |
(s)-3-amino-4-(naphthalen-2-ylamino)-4-oxobutanoic acid |
Q27162537 |
h-asp-bna |
l-aspartic acid alpha-(beta-naphthy-lamide) |
l-aspartic acid b-naphthylamide |
l-aspartic acid alpha -( beta -naphthylamide) |
Role | Description |
---|---|
chromogenic compound | Colourless, endogenous or exogenous pigment precursors that may be transformed by biological mechanisms into coloured compounds. They are used in biochemical assays and in diagnosis as indicators, particularly in the form of enzyme substrates. |
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Class | Description |
---|---|
amino acid amide | An amide of an amino acid formed formally by conversion of the carboxy group to a carboxamido group. |
N-(2-naphthyl)carboxamide | Any carboxamide resulting from the formal condensation of a carboxylic acid with 2-naphthylamine. |
L-aspartic acid derivative | A proteinogenic amino acid derivative resulting from reaction of L-aspartic acid at the amino group or either of the carboxy groups, or from the replacement of any hydrogen of L-aspartic acid by a heteroatom. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 2 (28.57) | 18.7374 |
1990's | 4 (57.14) | 18.2507 |
2000's | 1 (14.29) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 7 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |